NASDAQ:GWPH GW Pharmaceuticals (GWPH) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free GWPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$218.96▼$218.9650-Day Range$216.90▼$219.2852-Week Range$87.07▼$219.57VolumeN/AAverage Volume899,771 shsMarket Capitalization$6.86 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GW Pharmaceuticals alerts: Email Address Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About GW Pharmaceuticals Stock (NASDAQ:GWPH)GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Read More Ad Paradigm PressAI “wealth window” is closing June 25thToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… GWPH Stock News HeadlinesOctober 14, 2023 | powermag.comMelaka: Malaysia’s 2.2-GW Cutting-Edge Combined Cycle Gas Power PlantSeptember 28, 2023 | uk.investing.comGWPRF Historical DataMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.August 17, 2023 | usnews.comGeorge Washington UniversityMarch 9, 2023 | powermag.comChina Approves 106 GW of New Coal-Fired CapacityFebruary 19, 2023 | thestreet.comWhy Nasdaq-Traded Marijuana Stocks Remain UndervaluedSeptember 25, 2022 | investing.comGW Pharmaceuticals PLC (GWPRF)August 22, 2022 | benzinga.comMedical Marijuana Market Size Worth $40 Billion by 2028 at 19.2% CAGR, COVID-19 Impact and Global Analysis by The Insight PartnersMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.June 15, 2022 | thestreet.comWhy Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016March 3, 2022 | msn.comCourt Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW PharmaFebruary 15, 2022 | marketwatch.comMedical Marijuana Market Forecast With Trends, Challenges, Growth Drivers, And Top Key PlayersJanuary 25, 2022 | thestreet.comThese 3 Marijuana-Related Stocks Are Poised for Strong GrowthJanuary 21, 2022 | finance.yahoo.comGWPH Jan 2023 195.000 putDecember 15, 2021 | msn.comStudy Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy TreatmentNovember 1, 2021 | benzinga.comAadi Bioscience Appoints Scott Giacobello as Chief Financial OfficerOctober 26, 2021 | finance.yahoo.comToday's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW PharmaceuticalsOctober 26, 2021 | finance.yahoo.comGW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?August 4, 2021 | law360.com2 Firms Seek To Lead GW Pharma Suit Over $7.2B DealAugust 4, 2021 | msn.comJazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02BSee More Headlines Receive GWPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2020Today5/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GWPH CUSIPN/A CIK1351288 Webwww.gwpharm.com Phone44-12-2326-6800FaxN/AEmployees1,161Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,020,000.00 Net Margins-11.05% Pretax MarginN/A Return on Equity-7.46% Return on Assets-6.13% Debt Debt-to-Equity Ratio0.01 Current Ratio5.13 Quick Ratio4.31 Sales & Book Value Annual Sales$311.33 million Price / Sales22.05 Cash Flow$0.01 per share Price / Cash Flow18,588.22 Book Value$23.48 per share Price / Book9.33Miscellaneous Outstanding Shares31,349,000Free FloatN/AMarket Cap$6.86 billion OptionableOptionable Beta2.15 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Justin D. Gover (Age 50)CEO & Exec. Director Comp: $1.19MMr. Scott M. Giacobello (Age 51)Chief Financial Officer Comp: $743.33kMr. Douglas B. Snyder (Age 57)Chief Legal Officer & Sec. Comp: $787.02kDr. Volker Knappertz M.D. (Age 56)D.Sc., Chief Medical Officer Comp: $830.47kMr. Christopher John Tovey (Age 56)Chief Operating Officer Kristen CardilloVP of Corp. CommunicationMs. Tina St. LegerChief HR OfficerProf. Ben WhalleyHead of Discovery ResearchMr. Darren S. Cline (Age 57)U.S. Chief Commercial Officer More ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCICytokineticsNASDAQ:CYTKJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANBlueprint MedicinesNASDAQ:BPMCView All Competitors GWPH Stock Analysis - Frequently Asked Questions How were GW Pharmaceuticals' earnings last quarter? GW Pharmaceuticals plc (NASDAQ:GWPH) released its earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.27. The biopharmaceutical company earned $137.10 million during the quarter, compared to analysts' expectations of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. GW Pharmaceuticals's revenue for the quarter was up 50.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) EPS. What is Justin Gover's approval rating as GW Pharmaceuticals' CEO? 14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among the company's employees. What other stocks do shareholders of GW Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD). This page (NASDAQ:GWPH) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe Gold Grab of the CenturyColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024AltimetryGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GW Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
